Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 2/20 | 0.37 |
| ▸ | GABRD | O14764 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.37 |
| ▸ | GABRE | P78334 | 2/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.37 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.37 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.37 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288806 | 1.00 | SLC22A6 (0.39) | SLC22A6GABRR1LMNATDP1GABRP | |
| SCHEMBL636538 | 1.00 | SLC22A6 (0.39) | SLC22A6GABRR1LMNATDP1GABRP | |
| Hydrochloric Acid SCHEMBL14321732 | 0.97 | KDM4E (0.39) | SLC22A6GABRR1LMNATDP1GABRP | |
| Water SCHEMBL31634615 | 0.97 | SLC22A6 (0.38) | SLC22A6GABRR1LMNATDP1GABRP | |
| SCHEMBL7344981 | 0.82 | ADRA1A (0.40) | SLC22A6GABRR1LMNATDP1GABRP | |
| SCHEMBL289017 | 0.80 | ALDH1A1 (0.50) | SLC22A6GABRR1LMNATDP1GABRP | |
| SCHEMBL5144229 | 0.80 | ALDH1A1 (0.50) | SLC22A6GABRR1LMNATDP1GABRP | |
| SCHEMBL6776410 | 0.80 | CYP2D6 (0.37) | SLC22A6GABRR1LMNATDP1GABRP | |
| SCHEMBL15774508 | 0.79 | ECE1 (0.33) | LMNATDP1ALDH1A1MAPTPTGS1 | |
| SCHEMBL13007435 | 0.79 | ECE1 (0.33) | LMNATDP1ALDH1A1MAPTPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024022294-A9 | SPIROCHIRAL PLATINUM(II) AND PALLADIUM(II) COMPLEX CIRCULARLY POLARIZED LUMINESCENT MATERIAL AND USE THEREOF | 浙江工业大学 | 2024-09-26 | — | — | WO | disclosed |
| CN-117510547-A | Spiro chiral platinum (II) and palladium (II) complex circularly polarized luminescent material and application thereof | 浙江工业大学 | 2024-02-06 | — | — | CN | disclosed |
| WO-2024022294-A1 | SPIROCHIRAL PLATINUM(II) AND PALLADIUM(II) COMPLEX CIRCULARLY POLARIZED LUMINESCENT MATERIAL AND USE THEREOF | 浙江工业大学 | 2024-02-01 | — | — | WO | disclosed |
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-116836157-A | Oxadiazole derivative and preparation method and application thereof | 星希尔生物科技(上海)有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-109369635-B | Compound or pharmaceutically acceptable salt thereof, application thereof and pharmaceutical composition | 赛克里翁治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-113004252-B | Aryl imidazole derivative and application thereof | 江苏先声药业有限公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-3362451-B1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-04-12 | — | — | EP | disclosed |
| EP-3555095-B1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-04-12 | — | — | EP | disclosed |
| US-20230106002-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2009134977-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090274713-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| EP-1896409-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS USEFUL FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
| WO-2006137795-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS USEFUL FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | disclosed |
| EP-1695961-A1 | UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-7098341-B2 | Process for preparing haptens for immunoassay of phosphorothioate pesticides | Lee, Yong-Tae (KR) | 2006-08-29 | — | — | US | disclosed |
| WO-2005095325-A1 | PROCESS FOR THE PREPARATION OF β-AMINOCARBOXYLIC ACIDS | DEGUSSA AG (DE) | 2005-10-13 | — | — | WO | disclosed |
| EP-1098888-A1 | PIPERAZINONE DERIVATIVES AND THEIR USES | LABORATOIRE L. LAFON (FR) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004000-A1 | PIPERAZINONE DERIVATIVES AND THEIR USES | LABORATOIRE L. LAFON (FR) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106002-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | SLC22A6 2717/4885GABRR1 557/4885LMNA 3314/4885 |
| US-20090274713-A1 | CROSS-LINKERS AND THEIR USES | MTCL3, DCLRE1A, PCNA | SLC22A6 1588/4885GABRR1 787/4885LMNA 394/4885 |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | F2, URB2, F12 | SLC22A6 2675/4885GABRR1 3153/4885LMNA 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.